Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Angiolab Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SPAINE, ROBERT FRANKLIN. The portfolio is active in a distinct art unit.
SPAINE, ROBERT FRANKLIN is the busiest examiner for this portfolio, handling the 1 pending office action. As there is only the pending workload, the company's current prosecution experience is limited to this examiner and art unit. The distinct examiner and art unit represent the total footprint of the company's active patent office interactions. Practitioners should tailor their approach to the 1 pending office action based on the specific requirements of the Biotechnology & Pharmaceuticals sector. Analyzing the historical patterns of the busiest examiner can provide a roadmap for the pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPAINE, ROBERT FRANKLIN | 1 | 75.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580366 | COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT | SPAINE, ROBERT FRANKLIN | 13d |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18580366 | COMPOSITION COMPRISING HORSE CHESTNUT EXTRACT | SPAINE, ROBERT FRANKLIN | 1655 | §101§103 | Final Rejection | 13d | Pending | Jan 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial